“When tested in a small animal model of acute myeloid leukemia (AML), an aggressive and hard-to-treat blood cancer, the SNA-based version showed remarkable results. It entered leukemia cells 12.5 times more efficiently, destroyed them up to 20,000 times more effectively, and slowed cancer progression by a factor of 59, all without causing noticeable side effects.”
No comments:
Post a Comment